Algunas galaxias destacan por la violenta actividad que existe en su centro. Por regla general, esa actividad la genera un cuásar, un objeto astronómico cuyo motor es un agujero negro de masa enorme devorando material arremolinado en su entorno y provocando la emisión de chorros …
Si algún día la humanidad se topa con seres inteligentes de otro mundo, uno de los principales desafíos a los que se enfrentará nuestra civilización será el de entenderse con esas entidades. Por eso, parece sensato comenzar ahora por intentar comunicarse con …
Comunicarse con ballenas, requisito previo para poder comunicarse con extraterrestres Read More »
En computación cuántica, el bit cuántico o “qubit” es la unidad de información, como el bit convencional lo es en la computación convencional. Sin embargo, dotar de un soporte físico adecuado a los bits cuánticos es muchísimo má …
Primer procesador cuántico lógico operativo del mundo Read More »
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces it has completed its previously announced acquisition of assets related to Odyssey Health, Inc.’s (OTCQB: ODYY) (“Odyssey”) proprietary neurological drug therapies and technologies.
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets Read More »
Pulnovo Medical Limited recently announced that it has successfully obtained Humanitarian Use Device (HUD) designation from the US FDA and approval from China’s National Drug Administration (NMPA) for the PADN Catheter and Generator.
Better Therapeutics, Inc. today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for its novel PDT designed to treat metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis.
NRx Pharmaceuticals, Inc. today announced an update on plans to achieve compliance with Nasdaq market requirements related to minimum bid price and total Market Value of Listed Securities (MVLS).
NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard Read More »
Gannex Pharma Co., Ltd. (“Gannex”), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) announces today positive interim results from the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 tablet for treatment of patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).
Diakonos Oncology Corporation, a clinical stage immuno-oncology company, announced it has completed enrollment for its Phase 1 trial of DOC1021, a unique dendritic cell vaccine, for Glioblastoma Multiforme.
Noticias de la actualidad científica y tecnológica del 2 de enero de 2024. …
